Strategic Overview & R&D Interface
The Small Molecule Drug Series represents Hongtai Pharma's premier capability in supporting cutting-edge innovative drug development. Directly interfacing with active R&D pipelines including CS944X, CS3158, and CS410, these advanced building blocks and custom intermediates are engineered for elite biopharmaceutical laboratories and clinical-stage innovators.
Developing modern targeted therapeutics demands exceptional precision, complex multi-step execution, and stringent impurity control. Our dedicated synthesis taskforce collaborates closely with global research teams to deliver milligram-to-kilogram scale intermediates with complete analytical traceability.
Series Technical Parameters & Purity Standards
Every custom batch across the CS series undergoes rigorous telemetry screening and multi-sample HPLC/GC verification prior to release.
| Pipeline Series | Target Specification | Available Scale | Primary Application |
|---|---|---|---|
| CS944X Series | ≥ 99.0% (HPLC), Single Impurity < 0.1% | mg to kg Pilot Scale | Targeted Oncology R&D |
| CS3158 Series | ≥ 99.0% (HPLC), Strict Chiral Control | mg to kg Pilot Scale | Advanced Kinase Inhibition |
| CS410 Series | ≥ 99.5% (HPLC), Ultra-Low Moisture | mg to kg Pilot Scale | Innovative Therapeutic Pipeline |
Strict IP & Confidentiality
- Comprehensive Non-Disclosure Agreements (NDA)
- Isolated synthesis suites ensuring absolute security
- Complete chain-of-custody documentation
Seamless Scale-Up Agility
- Rapid transition from bench-scale to pilot production
- Direct consultation with senior process chemists
- Optimized synthetic routes minimizing impurity profiles